Show simple item record

dc.contributor.advisorRoy E. Welsch and Bernhardt Trout.en_US
dc.contributor.authorYoungman, Adam (Adam Joshua)en_US
dc.contributor.otherLeaders for Manufacturing Program.en_US
dc.date.accessioned2009-12-10T19:12:41Z
dc.date.available2009-12-10T19:12:41Z
dc.date.copyright2009en_US
dc.date.issued2009en_US
dc.identifier.urihttp://hdl.handle.net/1721.1/50101
dc.descriptionThesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Massachusetts Institute of Technology, Dept. of Materials Science and Engineering; in conjunction with the Leaders for Manufacturing Program at MIT, 2009.en_US
dc.descriptionIncludes bibliographical references (p. 53).en_US
dc.description.abstractNovartis Technical Operations is considering a complete overhaul of their manufacturing processes. To date, all drugs have been made by using a batch process. In an attempt to lower costs, Novartis is evaluating moving some drug production to a continuous process. Novartis has instituted lean in their production plants and it has been very successful, but what is on the table now is a way to bring lean to the highest level, and a chance to make a seismic shift in manufacturing performance. The continuous manufacturing initiative between Novartis and MIT exists to pursue that idea. My task was to evaluate the economic impact and feasibility of spray drying on drug manufacturing. Spray drying is an advanced manufacturing technique that could allow Novartis to skip multiple steps in chemical & pharmaceutical operations. It is also a process that can be used continuously. I investigated the use of spray drying with X, one of the drugs in Novartis' product pipeline. The major results of this investigation are that drug solubility in the solvent is a critical variable and that X is stable after spray drying. All experiments in the scientific section were performed with the drug dissolved in Ethanol, and all experiments resulted in stable versions of X combined with various additives. The drug solubility directly affects the number of spray dryers necessary for production within an allocated time span. Using economic assumptions that are detailed later in this work, there is a breakeven point for most drug volumes at around 3% drug solubility, assuming additives poses no problems for dissolution.en_US
dc.description.abstract(cont.) Despite economies of scale considerations and factory adjustments, this breakeven point is accurate for drug demands from 1 ton/year to 100 tons/year. Since my experiments were performed at 1.53% drug solubility (too low), I did not prove the economic viability of spray drying X in particular, but rather laid a framework for future studies.en_US
dc.description.statementofresponsibilityby Adam Youngman.en_US
dc.format.extent58 p.en_US
dc.language.isoengen_US
dc.publisherMassachusetts Institute of Technologyen_US
dc.rightsM.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.en_US
dc.rights.urihttp://dspace.mit.edu/handle/1721.1/7582en_US
dc.subjectSloan School of Management.en_US
dc.subjectMaterials Science and Engineering.en_US
dc.subjectLeaders for Manufacturing Program.en_US
dc.titleSpray drying as part of the continuous manufacturing value proposition at Novartisen_US
dc.typeThesisen_US
dc.description.degreeS.M.en_US
dc.description.degreeM.B.A.en_US
dc.contributor.departmentLeaders for Manufacturing Program at MITen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Materials Science and Engineering
dc.contributor.departmentSloan School of Management
dc.identifier.oclc462153126en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record